Fibrolamellar hepatocellular carcinoma

被引:22
|
作者
Smith, Mitchell T. [1 ]
Blatt, Ellen R. [2 ]
Jedlicka, Paul [2 ]
Strain, John D. [2 ]
Fenton, Laura Z. [2 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Radiol, Aurora, CO 80045 USA
[2] Childrens Hosp, Dept Radiol, Denver, CO 80218 USA
关键词
D O I
10.1148/rg.282075153
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
History A 13-year, 10-month-old boy presented with a low energy level, depression, and intermittent diarrhea. According to his growth chart, at age 7 years he was in the 25-50 percentile for height. At the time of presentation, he had fallen to the fifth percentile. Results of a bone age study indicated that his bone age, according to the standards of Gruelich and Pyle, was within 2 months of his chronologic age. Laboratory studies revealed the levels of free thyroxine and thyroid-stimulating hormone to be 12.6 pmol/L (normal range, 10.3-21.9 pmol/L) and 7.08 mIU/L (normal range, 0.36-5.4 uIU/mL), respectively. He began taking 50 mcg of Levothyroxine, which had a positive effect on his energy level. Results of physical examination at this time were remarkable for gynecomastia; the patient was referred for an endocrine evaluation. A month and a half later, the patient presented to the emergency department with shortness of breath and tachycardia. In addition, he experienced vomiting and diarrhea without fever over the previous 2 days. The patient's level of estrone was elevated at 777 pmol/L (normal range, 55.5-925 pmol/L), with estradiol at 8.1 pmol/L (normal range, 1.84-5.9), androstenedione at 2.2 nmol/L (normal range, 1.1-2.3), cortisol at 402.8 nmol/L (normal range, 140-690), and alpha-fetoprotein at 2.8 mu g/mL. Chest and abdominal computed tomography (CT) was ordered for a suspected pulmonary embolus and for liver abnormalities.
引用
收藏
页码:609 / 613
页数:5
相关论文
共 50 条
  • [1] Fibrolamellar Hepatocellular Carcinoma
    Shahi, Niharika
    Chung, Andrew David
    APPLIED RADIOLOGY, 2023, 52 (02) : 48A - 48C
  • [2] Fibrolamellar Hepatocellular Carcinoma
    Liu, Shu
    Chan, Kwok Wah
    Wang, Bingyuan
    Qiao, Liang
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (10): : 2617 - 2624
  • [3] Fibrolamellar hepatocellular carcinoma
    Koudah, Sabrina
    El Mouhadi, Sanaa
    Arrive, Lionel
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2012, 36 (01) : 5 - 6
  • [4] Fibrolamellar Hepatocellular Carcinoma
    Shigematsu, Yasuyuki
    Tanaka, Kazuhito
    Inamura, Kentaro
    INTERNAL MEDICINE, 2025,
  • [5] Managing fibrolamellar hepatocellular carcinoma
    Grandhi, Miral Sadaria
    Pawlik, Timothy M.
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (02): : 143 - 152
  • [6] FIBROLAMELLAR HEPATOCELLULAR-CARCINOMA
    FRIEDMAN, AC
    LICHTENSTEIN, JE
    GOODMAN, Z
    FISHMAN, EK
    SIEGELMAN, SS
    DACHMAN, AH
    RADIOLOGY, 1985, 157 (03) : 583 - 587
  • [7] Management of fibrolamellar hepatocellular carcinoma
    Chaudhari, Vikram A.
    Khobragade, Krunal
    Bhandare, Manish
    Shrikhande, Shailesh V.
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (05)
  • [8] Biomarker for fibrolamellar hepatocellular carcinoma
    Benmaamar, Ramla
    LANCET ONCOLOGY, 2014, 15 (04): : E156 - E156
  • [9] Fibrolamellar Hepatocellular Carcinoma Diagnosis
    Shah, Saumya M.
    Kamboj, Amrit K.
    Cleary, Sean P.
    GASTROENTEROLOGY, 2018, 155 (04) : E9 - E10
  • [10] FIBROLAMELLAR HEPATOCELLULAR-CARCINOMA
    HUBER, M
    MEIER, J
    MEIER, P
    SCHMID, M
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1986, 116 (34) : 1154 - 1158